Evidence that this approach is a useful one can be found in the fact that experimental and clinical studies have shown that agents that target the HIF1A/VEGF network can decrease tumor growth and prolong survival in both animals and humans [60,61]. This evidence concerns the gene VEGFA and neoplasm.